3. Sanofi-Aventis France n'a pas mi

3. Sanofi-Aventis France n'a pas mis en place de strategie globale et structuree

163. La Decision affirme que Sanofi-Aventis France aurait mis en place une « communication globale et structuree »76 dans le cadre du lancement des generiques de Plavix.

164. Selon la Decision, « Cette strategie de communication a ainsi pris la forme d'un discours public de
Sanofi-Aventis fors du lancement des g(meriques de Plavix® et d'une serie d'argumentaires distribues par Sanofi-Aventis et BMS a leurs forces commerciales. » 77

165. Or, i1 n'existe aucun element probant78 etablissant l'existence d'une telle « strategie » de la part de
Sanofi-Aventis France, pour la bonne raison qu'une telle strategie n'a jamais existe.

166. Premierement, la Decision ne cite aucune declaration ambigue ou douteuse de la part des visiteurs medicaux de Sanofi-Aventis France, alors que ce sont eux qui sont censes avoir delivre l'information soi-disant abusive.

167. La seule declaration citee dans la Decision emanant d'un employe de Sanofi-Aventis France concerne le propos suivant tenu par une deleguee pharmaceutique :

« Un patient qui fait un syndrome coronaire, c'est un patient qui a un haut risque de recidiver ou de mourir. Plavix a fait l'objet d'essais cliniques. Par rapport aux generiques, qui n'auraient pas (au
conditionnel, car a l'epoque nous ne connaissions pas tous les generiques) toutes les indications,
cela permet au patient d'avoir le traitement de reference. »79

Résultats (Anglais) 1:

3. sanofi-aventis France has not implemented comprehensive and structured strategy

163. The decision states that sanofi-aventis France would set up a "comprehensive and structured communication" 76 in the launch of the generic plavix.
164. according to the decision, "This communication strategy has taken the form of a public discourse
sanofi-aventis fors launch of g (MERICAS of plavix ® and a series of arguments distributed by sanofi-aventis and BMS to their sales forces. "77
165. gold i1 is no evidence to show the probant78 existence of such a "strategy" from
sanofi-aventis France, for the reason that such a strategy was never there.
166. firstly,The decision cites no ambiguous or doubtful statement from the medical visitors sanofi-aventis France, while they are the ones who are supposed to have issued the so-called information abusive.
167. the only statement cited in the decision emanating from an employee of sanofi-aventis France concerned about the next run by a pharmaceutical Representative:

"A patient who coronary syndrome, this is a patient who has a high risk of reoffending or die. plavix has been the subject of clinical trials. compared to generic, which would not (conditional
as at the relevant time we did not know all the Internet) all indications
it allows the patient to the treatment of reference. "79

Résultats (Anglais) 2:

3 Sanofi-Aventis France has not put in place of strategy comprehensive and structured

163. The Decision says that Sanofi-Aventis France would set up a "global communication and structured' 76 for the launch of generic Plavix.

164. According to the Decision, "this communication strategy thus took the form of a public speech by
Sanofi-Aventis fors of the launch of the g(meriques de Plavix® et d'une serie d'argumentaires distribues par Sanofi-Aventis et BMS a leurs forces commerciales.) ' 77

165. However, i1 no element exists probant78 establishing the existence of such a "strategy" on the part of
Sanofi-Aventis France, for the good reason that such a strategy has never exists.

166. First, the Decision cites no ambiguous statement or dubious from the Sanofi-Aventis France medical visitors, then what are the ones who are supposed to have issued the so-called abusive information.

167. The only statement quoted in Decision emanating from an employee of Sanofi - Aventis France concerns the following remarks by a pharmaceutical delegate:

A patient who is coronary syndrome, it is a patient who has a high risk of given or die. Plavix has been the subject of clinical trials. Compared to generics, that would not (in the
conditional, because at the time we knew not all generics) all indications,
this allows the patient to have the standard treatment. ' 79
.

Résultats (Anglais) 3:

3. Sanofi-Aventis France has not put in place a comprehensive strategy and structured

163. The Decision affirms that Sanofi-Aventis France would have put in place a "global communication and structured "76 in the context of the launch of generic Plavix.

164. According to the Decision, "This communication strategy has thus taken the form of a public speech of
Sanofi-Aventis fors the launch of g(like digital cameras of Plavixâ® and a series of pitches distributed by Sanofi-Aventis and BMS has their commercial forces. " 77

165. However, i1 there is no evidence78 establishing the existence of such a "strategy" on the part de
Sanofi-Aventis France, for the good reason that such a strategy has never existed.

166. First,The Decision did not cite any statement ambiguous or doubtful of the share of medical visitors of Sanofi-Aventis France, whereas they are the ones who are supposed to have issued the information so-called abusive.

167. The only statement quoted in the Decision from an employee of Sanofi-Aventis France concerned about the next held by a delegate pharmaceutical:

"A patient who makes a coronary syndrome, this is a patient who has a high risk to reoffend or die. Plavix has been the subject of clinical trials. In relation to the generic, which would not (at
conditional, because at the time we did not know all the generic) all indications,
This allows the patient to have the reference treatment. " 79